Streetbeat News

NRXP

NRx Pharmaceuticals, Inc.

https://www.nrxpharma.com

Industry

Biotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

Open

2.09

Mkt cap

40M

Volume

242K

High

2.40

P/E Ratio

-1.11

52-wk high

6.01

Low

2.08

Div yield

N/A

52-wk low

1.10

NRx Pharmaceuticals announced the launch of HOPE Therapeutics at the BIO CEO & Investor Conference 2024, proposing to award 50% of founding shares to current shareholders along with a royalty coupon, contingent on board approval. The dividend is tied to a covenant against short selling NRx stock. HOPE plans to have ketamine supplies ready for shipment under 503a pharmacy regulations by July 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:32 pm

NRx Pharmaceuticals has received a $5M milestone payment from Alvogen and Lotus Pharmaceutical, extending its cash runway. The payment is part of an agreement that could see NRx eligible for up to $324M in additional milestones, plus royalties, upon NRX-101's approval and commercialization.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:35 pm

NRx Pharmaceuticals announced the creation of Hope Therapeutics to focus on NRX-100 (now HTX-100), aimed at treating suicidal depression. NRx and its shareholders will own the new company, receiving shares as a dividend plus a royalty coupon on HTX-100 sales, pending Board approval. The arrangement is structured to avoid taxation for shareholders.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 11:52 am

NRx Pharmaceuticals, Inc. (NRXP) received a positive determination from the Nasdaq Hearings Panel for its listing transfer to The Nasdaq Capital Market. The company must demonstrate compliance with a $35 million market value of listed securities and a $1.00 minimum bid price by April 16, 2024. NRx believes it has met the market value requirement and is working to meet the bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

January 17, 2024 | 11:51 am

NRx Pharmaceuticals has been granted FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for NRX-101, aimed at treating complicated urinary tract infections and pyelonephritis. These designations could expedite the development and review process for NRX-101, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

January 16, 2024 | 11:52 am

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:45 pm

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) has announced its plans to comply with Nasdaq's minimum bid price and Market Value of Listed Securities (MVLS) requirements. The company previously received two deficiency notices from Nasdaq for not maintaining a minimum $1 bid price and an MVLS of $50 million. NRx Pharmaceuticals intends to present a full compliance plan to Nasdaq by January 4, 2024, which will be based on achieving clinical milestones.

Portfolio Pulse from Charles Gross

January 02, 2024 | 11:55 am

In Tuesday's after-market session, several healthcare stocks experienced significant movements. Aclarion (ACON) saw a substantial increase of 59.9%, while Clene (CLNN), Acutus Medical (AFIB), Avinger (AVGR), Blue Water Biotech (BWV), and Biora Therapeutics (BIOR) also gained. Conversely, Biophytis (BPTS), Guardant Health (GH), Syros Pharmaceuticals (SYRS), Alzamend Neuro (ALZN), Ensysce Biosciences (ENSC), and NRX Pharmaceuticals (NRXP) faced declines, with Biophytis leading the losses.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 9:31 pm

NRx Pharmaceuticals has entered into an agreement with Columbia University for the rights to data from a trial on the effectiveness of Ketamine in treating acute suicidality in depression. The trial showed Ketamine to be highly effective, and NRx plans to use this data to support a New Drug Application to the FDA in Q1 2024.

Portfolio Pulse from Benzinga Newsdesk

December 19, 2023 | 1:19 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant movements. Biomerica, Cingulate, Arcutis Biotherapeutics, Panbela Therapeutics, NRX Pharmaceuticals, and Alaunos Therapeutics saw their shares rise by 54.5%, 33.33%, 31.14%, 30.54%, 30.08%, and 29.89% respectively. Conversely, Minerva Surgical, Checkpoint Therapeutics, Structure Therapeutics, Lantheus Holdings, Ainos, and Blue Water Biotech faced declines of 52.5%, 50.31%, 45.24%, 18.8%, 18.08%, and 16.08% respectively.

Portfolio Pulse from Benzinga Insights

December 19, 2023 | 1:07 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.